Clinical Trials Browser

Phase 3 × INDUSTRY × Leukemia, Myeloid, Acute × Clear all

NCT05429632 2026-04-17

MO-TRANS

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06852222 2026-04-13

cAMeLot-2

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07007312 2026-04-09

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04102020 2026-04-08

VIALE-M

Phase 3 Completed

112 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06578247 2026-03-31

QuANTUM-WILD

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT07211958 2026-03-25

REVEAL-ND NPM1

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03844048 2026-03-20

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05316701 2026-03-04

Orca-T

Phase 3 Active not recruiting

187 enrolled 15 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02730299 2026-02-25

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3 Completed

125 enrolled 18 charts 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03182244 2026-02-06

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Phase 3 Active not recruiting

276 enrolled 41 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase 3 Completed

371 enrolled 36 charts 2 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06389292 2025-11-25

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03173248 2025-11-10

AGILE

Phase 3 Active not recruiting

146 enrolled 11 charts 2 FDA

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT03268954 2025-10-29

PANTHER

Phase 3 Completed

454 enrolled 41 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04161885 2025-10-06

VIALE-T

Phase 3 Terminated

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Phase 3 Completed

211 enrolled 30 charts 2 FDA

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02752035 2025-09-12

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Phase 3 Completed

183 enrolled 30 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

Phase 3 Active not recruiting

443 enrolled 14 charts 2 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06387069 2025-08-14

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 1 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05054543 2025-06-27

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Phase 3 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05907057 2025-04-11

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05586074 2025-04-09

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05079230 2025-04-04

ENHANCE-3

Phase 3 Terminated

378 enrolled 29 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05883956 2025-03-20

PREFER-HMA

Phase 3 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

NCT04778397 2025-02-05

ENHANCE-2

Phase 3 Terminated

258 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02997202 2025-01-17

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Phase 3 Completed

356 enrolled 22 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02920008 2024-08-28

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Phase 3 Completed

302 enrolled 23 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02348489 2024-08-27

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Phase 3 Completed

815 enrolled 19 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Phase 3 Completed

227 enrolled 37 charts 2 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02668653 2024-08-06

QuANTUM-First

Phase 3 Completed

539 enrolled 20 charts 2 FDA

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT03616470 2024-07-29

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Phase 3 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04571645 2024-04-15

AML

Phase 3 Terminated

9 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03379727 2024-02-29

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Phase 3 Completed

301 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05020665 2024-01-10

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

Phase 3 Terminated

15 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06182592 2023-12-28

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

Phase 3 Not yet recruiting

Other hematologic neoplasm

Neoplasm Metastasis, Leukemia, Myeloid, Acute

NCT04842604 2023-12-18

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Phase 3 Completed

14 enrolled 11 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03512197 2023-08-21

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Phase 3 Completed

511 enrolled 26 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT02665065 2023-07-19

SIERRA

Phase 3 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03416179 2023-04-21

BRIGHT AML1019

Phase 3 Completed

730 enrolled 35 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03941964 2023-03-20

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Phase 3 Completed

60 enrolled 12 charts

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT01721876 2023-02-08

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Phase 3 Completed

666 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03504410 2023-02-08

Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML

Phase 3 Terminated

200 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04095858 2023-02-08

CATHY

Phase 3 Terminated

11 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01303796 2022-06-22

SEAMLESS

Phase 3 Completed

482 enrolled 24 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02999854 2022-05-24

HATCY

Phase 3 Terminated

63 enrolled 14 charts

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04509622 2022-05-05

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

Phase 3 Completed

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT03151408 2022-03-10

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Phase 3 Terminated

406 enrolled 30 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute